Publications by authors named "Juan Manuel Palacios"
Background: Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes. This study evaluated real-world practice among urologists treating patients receiving 5-alpha reductase inhibitors.
Methods: This non-interventional, cross-sectional study collected data from urologists in Spain (N = 100) and Brazil (N = 100) via a self-reporting questionnaire and patient record forms.
Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
Prostate Cancer Prostatic Dis
September 2024
Article Synopsis
- This study looked at how different treatments for prostate problems affect symptoms like needing to go to the bathroom often, trouble starting to pee, and nighttime trips to the bathroom.
- Researchers used data from a specific study to see which treatments helped the most and what factors (like age and previous treatments) influenced these results.
- They found that combination therapy was better than single treatments for most patients and created an interactive tool online to show these results clearly.
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
World J Urol
March 2017
Article Synopsis
- The study aimed to explore how lifestyle changes can help men with moderate benign prostatic hyperplasia (BPH) who are at risk of worsening symptoms.
- Patients were divided into two groups: one received a combination medication (dutasteride and tamsulosin) while the other was monitored without immediate treatment, following their symptoms over 24 months.
- Findings suggested that lifestyle advice and no treatment showed similar symptom improvements, indicating that baseline quality of life measures (BPH Impact Index) could be more important than just symptom severity when considering medical treatment options.
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
BJU Int
September 2015
Article Synopsis
- The study aimed to compare the effectiveness of a fixed-dose combination of dutasteride and tamsulosin against a watchful waiting approach in men with moderate benign prostatic hyperplasia (BPH).
- In a trial with 742 participants, results showed that those receiving the combination therapy had significantly greater symptom relief and improved quality of life compared to the watchful waiting group after 24 months.
- The combination therapy also reduced the risk of BPH progression by over 43%, indicating it is a more effective treatment option for men at risk of worsening symptoms.
Objective. To assess the impact of low-to-moderate risk prostate cancer on patients' quality of life (QoL) at diagnosis and within the first year of treatment. Subjects and Methods.
View Article and Find Full Text PDFProkaryotic cell division protein FtsZ, an assembling GTPase, directs the formation of the septosome between daughter cells. FtsZ is an attractive target for the development of new antibiotics. Assembly dynamics of FtsZ is regulated by the binding, hydrolysis, and exchange of GTP.
View Article and Find Full Text PDF